Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.

Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.

Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: A technique is described herein for facilitating movement of graphical objects across display screens. In one manner of operation, the method includes: displaying a representation of a first movement as a user moves a graphical object across a source screen; detecting that the user has moved the graphical object into a graphical source portal associated with the source screen; associating the graphical object with two or more graphical destination portals provided by the plural display screens, in addition to the graphical source portal, such that the graphical object is accessible from the graphical source portal and any graphical destination portal; detecting that the user has removed the graphical object from a chosen graphical portal in a chosen screen; displaying the graphical object as having been removed from all graphical portals; and displaying a second movement as the user moves the graphical object across the chosen screen to a final destination.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: Implementations described herein provide a component system that reconfigures interchangeable computing device components based on a current state of the computing device. The current state of the computing device is determined based on a hardware configuration of the device, a shell configuration describing software and firmware of the device, and/or context information describing a relationship between the device and its surrounding environment. Based on the current state of the computing device, an output is determined that specifies interchangeable components are to be activated and deactivated. The output is useable to reconfigure individual computing device functionalities, control a manner in which applications execute on the computing device, and adapt the computing device to its current state.

Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an \JD antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor M specific antigen naturally occurring on the surface of a minor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.

Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T) cell assays to test novel antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a recognition domain of an antigen binding molecule. The invention also relates to methods and kits for specificity testing of a candidate antigen binding moiety and/or nucleic acid molecules and vectors expressing engineered CARs.

Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T cell) assays to test antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a target antigen, e.g., tumor associated antigens.

Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

Abstract: In one example, a method for detecting input can include detecting a capacitive pattern from a physical object and detecting that the physical object is a passive physical object. The method can also include determining a plurality of characteristics corresponding to the passive physical object based on the capacitive pattern, wherein the plurality of characteristics comprise a type of the physical object and a capability of the physical object. Additionally, the method can include modifying an application manager to detect input from the passive physical object based on the plurality of characteristics and modifying a user interface setting detected from the capacitive pattern.

Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.

Abstract: Techniques for input adjustment are described. In one or more implementations, a user perspective of a display surface is estimated, and is used to correlate output that is displayed on the display surface. According to one or more implementations, detected motion of a display surface is used to compensate for an effect of the motion on input to the display surface.

Abstract: The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.

Abstract: A digital inking device can automatically adapt its interaction modality to provide contextually relevant status information and contextually relevant user interface control elements based on a user's activity. An interaction model of a digital inking device can automatically adapt the display of particular control user interface control elements and particular status indicators based on one or more factors. For example, a digital inking device can select an interaction model from a number of interaction models based on a way a digital inking device is held by a user, a fingerprint of a user, an angle and/or distance of a digital inking device with respect to a paired computer, a particular grip a user has on a digital inking device, an amount of pressure that is used to hold a digital inking device, a contact pressure between a digital inking device and a paired computer, and/or one more gestures performed by a user.